SignatureFD’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.47M | Buy |
5,526
+221
| +4% | +$103K | 0.04% | 189 |
|
|
2025
Q4 | $2.41M | Buy |
5,305
+202
| +4% | +$87.1K | 0.04% | 186 |
|
|
2025
Q3 | $2M | Sell |
5,103
-197
| -4% | -$82.3K | 0.03% | 220 |
|
|
2025
Q2 | $2.36M | Sell |
5,300
-405
| -7% | -$187K | 0.04% | 173 |
|
|
2025
Q1 | $2.77M | Buy |
5,705
+656
| +13% | +$306K | 0.05% | 142 |
|
|
2024
Q4 | $2.03M | Sell |
5,049
-100
| -2% | -$46.4K | 0.04% | 172 |
|
|
2024
Q3 | $2.39M | Buy |
5,149
+55
| +1% | +$26.4K | 0.05% | 147 |
|
|
2024
Q2 | $2.39M | Sell |
5,094
-190
| -4% | -$82.5K | 0.05% | 138 |
|
|
2024
Q1 | $2.21M | Buy |
5,284
+388
| +8% | +$164K | 0.05% | 149 |
|
|
2023
Q4 | $1.99M | Buy |
4,896
+448
| +10% | +$165K | 0.05% | 150 |
|
|
2023
Q3 | $1.55M | Buy |
4,448
+308
| +7% | +$108K | 0.04% | 172 |
|
|
2023
Q2 | $1.46M | Buy |
4,140
+386
| +10% | +$130K | 0.04% | 181 |
|
|
2023
Q1 | $1.18M | Buy |
3,754
+272
| +8% | +$81.6K | 0.03% | 210 |
|
|
2022
Q4 | $1.01M | Buy |
3,482
+125
| +4% | +$38.1K | 0.03% | 233 |
|
|
2022
Q3 | $972K | Buy |
3,357
+388
| +13% | +$112K | 0.03% | 201 |
|
|
2022
Q2 | $837K | Buy |
2,969
+332
| +13% | +$88.9K | 0.03% | 233 |
|
|
2022
Q1 | $688K | Buy |
2,637
+330
| +14% | +$78.3K | 0.02% | 299 |
|
|
2021
Q4 | $507K | Buy |
2,307
+631
| +38% | +$123K | 0.02% | 393 |
|
|
2021
Q3 | $304K | Sell |
1,676
-1,636
| -49% | -$319K | 0.01% | 536 |
|
|
2021
Q2 | $668K | Buy |
3,312
+3
| +0.1% | +$628 | 0.03% | 269 |
|
|
2021
Q1 | $711K | Buy |
3,309
+264
| +9% | +$58K | 0.03% | 229 |
|
|
2020
Q4 | $720K | Buy |
3,045
+1,044
| +52% | +$240K | 0.03% | 193 |
|
|
2020
Q3 | $545K | Sell |
2,001
-36
| -2% | -$9.93K | 0.03% | 220 |
|
|
2020
Q2 | $591K | Buy |
2,037
+398
| +24% | +$108K | 0.04% | 188 |
|
|
2020
Q1 | $390K | Buy |
1,639
+270
| +20% | +$61.9K | 0.03% | 236 |
|
|
2019
Q4 | $300K | Buy |
1,369
+143
| +12% | +$28.9K | 0.02% | 362 |
|
|
2019
Q3 | $208K | Buy |
1,226
+210
| +21% | +$37.1K | 0.02% | 396 |
|
|
2019
Q2 | $186K | Buy |
1,016
+72
| +8% | +$12.6K | 0.02% | 417 |
|
|
2019
Q1 | $174K | Sell |
944
-8
| -0.8% | -$1.48K | 0.01% | 433 |
|
|
2018
Q4 | $158K | Buy |
952
+191
| +25% | +$33.1K | 0.01% | 433 |
|
|
2018
Q3 | $147K | Buy |
761
+22
| +3% | +$3.92K | 0.01% | 511 |
|
|
2018
Q2 | $126K | Sell |
739
-62
| -8% | -$9.61K | 0.01% | 534 |
|
|
2018
Q1 | $131K | Buy |
+801
| New | +$131K | 0.02% | 449 |
|
|
2016
Q4 | – | Sell |
-453
| Closed | -$40K | – | 1203 |
|
|
2016
Q3 | $40K | Buy |
453
+126
| +39% | +$11.9K | 0.01% | 593 |
|
|
2016
Q2 | $28K | Buy |
327
+22
| +7% | +$1.9K | ﹤0.01% | 634 |
|
|
2016
Q1 | $24K | Buy |
305
+54
| +22% | +$4.88K | ﹤0.01% | 617 |
|
|
2015
Q4 | $32K | Buy |
251
+173
| +222% | +$20.9K | 0.01% | 454 |
|
|
2015
Q3 | $8K | Buy |
78
+68
| +680% | +$8.74K | ﹤0.01% | 740 |
|
|
2015
Q2 | $1K | Buy |
+10
| New | +$1.26K | ﹤0.01% | 1009 |
|
Other funds holding VRTX
VCM
VPM
SignatureFD's VRTX Position: Q1 2026 in Review
SignatureFD increased its Vertex Pharmaceuticals (VRTX) stake by 4.2% in Q1 2026, buying an estimated $103K and bringing the position to 5,526 shares worth $2.47M. The position accounts for 0.04% of the portfolio, ranked #189.
SignatureFD first reported a position in VRTX in Q2 2015 and has held it in 39 quarters since. The position peaked at $2.77M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- SignatureFD held 5,526 shares of Vertex Pharmaceuticals worth $2.47M as of Q1 2026.
- SignatureFD bought 221 Vertex Pharmaceuticals shares in Q1 2026, an estimated $103K.
- Vertex Pharmaceuticals made up 0.04% of SignatureFD's portfolio in Q1 2026, its #189 holding.
- SignatureFD first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 39 quarters since.
- SignatureFD's Vertex Pharmaceuticals position peaked at $2.77M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.